Drugs / RC88
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05804526 | Jul 2023 → May 2025 | cancer | RemeGen Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05508334 | Jan 2023 → Nov 2025 | cancer | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04175847 | Apr 2020 → Dec 2025 | cancer | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06173037 | Jan 2024 → Dec 2025 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06016062 Background | Sep 2023 → Dec 2025 overdue | cancer | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-01-08 | RemeGen Co., Ltd. | Regulatory RemeGen’s ADC RC88 Targeting MSLN in Patients with Ovarian Cancer and Other Tumors Obtained FDA Fast Track Designation remegen.com ↗
On January 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announced that its independently developed ADC, RC88, has been granted fast track designation (FTD) by the FDA for the treatment of platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. |
| 2023-12-19 | RemeGen Co., Ltd. | Regulatory FDA Grants IND Approval to RemeGen’s RC88 Targeting MSLN for Phase 2 Ovarian Cancer Treatment remegen.com ↗
It has been approved by US FDA, and will be performed in the US, China, European Union, and other countries and regions. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-01-08 | RemeGen Co., Ltd. | RemeGen’s ADC RC88 Targeting MSLN in Patients with Ovarian Cancer and Other Tumors Obtained FDA Fast Track Designation remegen.com ↗ |
| 2023-12-19 | RemeGen Co., Ltd. | FDA Grants IND Approval to RemeGen’s RC88 Targeting MSLN for Phase 2 Ovarian Cancer Treatment remegen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RC88 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05804526 ↗ |
| Route | Intravenous | “intravenous infusion of RC88” NCT05508334 ↗ |